GLP-1 Advisor | One Day MD

Updated October 3, 2026 GLP-1 therapy has moved far beyond the simple phrase “weight-loss drugs.” Semaglutide, tirzepatide and newer oral and multi-receptor therapies are reshaping obesity, diabetes and cardiometabolic care. But a useful GLP-1 guide needs two columns: what these medicines can do, and what they can cost if treatment is poorly matched, escalated too quickly, or accompanied by inadequate nutrition and physical activity. This GLP-1 manual brings the major evidence together in one place: the drug family, approved 2026 therapies, emerging candidates, expected weight loss, cardiovascular and kidney outcomes, liver and sleep-apnea data, adverse effects, contraindications, oral contraceptive issues, peri-procedural considerations, muscle and bone preservation, monitoring and what happens when treatment is stopped. The central idea: GLP-1 therapy should not be judged by the scale alone. The clinically meaningful goal is better health w...

The obesity-drug market has entered a new phase. Eli Lilly and Novo Nordisk remain central to the global obesity-treatment market, but the competitive landscape in 2026 is no longer simply a two-company race between tirzepatide and semaglutide. Oral GLP-1 therapies are now commercial products. Next-generation dual and triple agonists have generated substantial clinical weight-loss results. Amylin-based medicines have moved into late-stage development. Long-acting therapies are testing less-frequent dosing, while combination strategies are attempting to address multiple biological pathways simultaneously. Important: Clinical-stage drugs discussed in this article are investigational unless explicitly identified as approved. Weight-loss percentages reported from different clinical trials should not be interpreted as direct head-to-head comparisons unless the drugs were tested against each other in the same randomized trial. Many figures below come from company-reported topli...